Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2019-05-07 Interim / Quarterly Rep…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
Interim / Quarterly Report Classification · 1% confidence The document is an earnings release from Verona Pharma plc for the three months ended March 31, 2019. It contains key financial highlights (net cash, operating loss, loss per share) and operational updates (clinical trial progress). While it mentions that an electronic copy of the interim results will be made available, the document itself provides the substantive financial data and analysis for the quarter, qualifying it as an Interim/Quarterly Report (IR) rather than a mere announcement (RPA). Q1 2019
2019-05-07 English
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
Regulatory Filings Classification · 1% confidence The document is a press release, indicated by the structure, the date/location stamp (LONDON, May 07, 2019), and the inclusion of contact information for media and investors, often distributed via services like GlobeNewswire. The content announces the initiation of a Phase 2b clinical study for a drug candidate (ensifentrine) and provides updates on expected data timelines and future trial plans (Phase 3 in 2020). This type of announcement, focusing on operational/clinical progress rather than comprehensive financial results (like a 10-K or IR) or a formal earnings summary (ER), is best classified as a general announcement. Since it is not a specific filing like a Director's Dealing (DIRS), Capital Update (CAP), or Dividend Notice (DIV), and it is not merely announcing the publication of another report (RPA), it falls under the general regulatory/news announcement category, which corresponds to Regulatory Filings (RNS) as the most appropriate fallback for non-standard, material news releases.
2019-05-07 English
Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
Report Publication Announcement Classification · 1% confidence The document is a press release dated May 1, 2019, announcing that Verona Pharma plc will report its audited financial results for the first quarter ended March 31, 2019, on May 7, 2019. It also announces a conference call to discuss these results and provide a clinical update. This structure—announcing the release of periodic financial results and scheduling a call—is the primary characteristic of an Earnings Release (ER). It is not the full report itself (like 10-K or IR), nor is it a transcript of the call (CT). It is the initial announcement of the results.
2019-05-01 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document text is very short (1498 characters) and contains an 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, immediate operational announcement rather than a comprehensive financial report (like 10-K or IR) or a standard corporate action announcement (like DIV or ER). Since it is a direct, non-standard regulatory announcement disseminated via the RNS system, and it doesn't fit perfectly into the other specific categories (like DIRS, MANG, or DIV), the most appropriate classification is the general regulatory filing fallback category, RNS.
2019-04-26 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1481 characters) and contains an 'RNS Number' and mentions the 'London Stock Exchange'. The content describes an extension of the 'Price Monitoring' auction call period, which is a specific operational announcement related to trading mechanics. This type of general, non-financial regulatory update that doesn't fit into specific categories like earnings, dividends, or director dealings is best classified under the general regulatory announcement category, RNS (Regulatory Filings), as it is explicitly sourced from RNS and relates to market operations.
2019-04-26 English
Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
Regulatory Filings Classification · 1% confidence The document is a press release from Verona Pharma plc announcing an upcoming 'investor and analyst R&D forum' scheduled for May 8th. It details the topics to be covered (COPD, ensifentrine) and mentions that a live webcast will be available. This type of announcement, which informs investors about a specific event designed to present company strategy, pipeline updates, and financial outlook, aligns best with the Investor Presentation (IP) category, as it is a structured event for investors, even if it's not a traditional slide deck. However, since the document itself is an announcement *about* an event, and not the presentation materials or a transcript, it could also be considered a general Regulatory Filing (RNS) or potentially a Report Publication Announcement (RPA) if it were announcing the release of a formal report. Given the focus on presenting R&D insights and strategy to investors, 'Investor Presentation (IP)' is the most specific fit for the *content* being promoted. However, following Rule 2 (Menu vs Meal), this is an announcement of an event, not the presentation itself. It is not a standard earnings release (ER) or a formal report (10-K, IR). It is a specific announcement about an investor event. Since there isn't a specific code for 'Event Announcement', and it's not a formal report release announcement (RPA), the most appropriate general category for a specific, non-standard corporate update is Regulatory Filings (RNS). I will classify it as RNS as it is a specific corporate communication that doesn't fit the other defined categories well, although IP describes the nature of the event being announced.
2019-04-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.